Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing a fixed-dose combination of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) versus darunavir/cobicistat with emtr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) FDC
• Emtricitabine/Tenofovir Disoproxil Fumarate (ETDF/FTC + TDF FDC)
• darunavir/cobicistat (darunavir/cobicistat)

Snippet

Sponsor: Janssen Sciences Ireland UC | Conditions: Immunodeficiency Virus Type 1, Human | Phase 3 | Status: COMPLETED | Results posted: 2018-09-14